102
Views
6
CrossRef citations to date
0
Altmetric
Review

Degarelix and its therapeutic potential in the treatment of prostate cancer

, &
Pages 215-223 | Published online: 05 May 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Gábor Mező & Marilena Manea. (2009) Luteinizing hormone-releasing hormone antagonists. Expert Opinion on Therapeutic Patents 19:12, pages 1771-1785.
Read now

Articles from other publishers (5)

D. S. Plevako, M. S. Knyazeva, E. I. Sidina, M. V. Berkut, S. A. Reva, S. S. Tolmachev, A. S. Artemyeva, A. K. Nosov & A. V. Malek. (2022) Effect of taxanes on the miR-106 and miR-200c expression in prostate cancer cells in vivo and in vitro. Urology Herald 10:4, pages 98-108.
Crossref
Ivan Guryanov, Andrea Orlandin, Angelo Viola, Barbara Biondi, Fernando Formaggio, Antonio Ricci & Walter Cabri. (2020) Overcoming Chemical Challenges in the Solid-Phase Synthesis of High-Purity GnRH Antagonist Degarelix. Part 2. Organic Process Research & Development 24:2, pages 274-278.
Crossref
Ivan Guryanov, Andrea Orlandin, Angelo Viola, Barbara Biondi, Denis Badocco, Fernando Formaggio, Antonio Ricci & Walter Cabri. (2019) Overcoming Chemical Challenges in the Solid-Phase Synthesis of High-Purity GnRH Antagonist Degarelix. Part 1.. Organic Process Research & Development 23:12, pages 2746-2753.
Crossref
Putri Ayu Jayusman, Isa Naina Mohamed & Ahmad Nazrun Shuid. (2018) The Effects of Chemical Castration with Degarelix on Bone Turnover: Densitometric and Biomechanics Bone Properties of Male Rats. International Journal of Endocrinology and Metabolism 16:3.
Crossref
Emily Patrick, Melissa Whitson, Amy Smith, Jamin Parnell, Suzanne E. Thomas & Clint C. Blankenship. (2013) GnRH receptor antagonists for prostate cancer. Journal of the American Academy of Physician Assistants 26:7, pages 51-52.
Crossref